Brought to you by 
Series C round brings $79mm to Proteolix
08 Sep 2008
Executive Summary
Proteolix (treatments for cancer and autoimmune diseases) raised $79mm through a Series C round led by new investor Nomura Phase4 Ventures. Additional new buyer Westfield Capital Management also participated, along with returning backers Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, US Venture Partners, and the Vertical Group. Proceeds from the financing will be put towards Phase II and III clinical trials of Proteolix's carfilzomib for multiple myeloma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C round brings $79mm to Proteolix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice